ArticleInternational journal of nanomedicine2025
Reduction-Responsive Nanoparticles Self-Assembled from Sericin-ss-Doxorubicin Conjugate for Hydrophobic IR780 Delivery with Integration of Antitumor Chemo-Phototherapy.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Silica based nanocarriers for combination immunotherapy targeting the tumor immune microenvironment.Drug delivery and translational research · 2026Review
- Article
- The intersection of ferroptosis and non-coding RNAs: a novel approach to lung cancer.Irish journal of medical science · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stimuli-responsive polymer-drug nanoparticles have emerged as a versatile and effective platform for delivering drugs in the treatment of malignant tumors. The integration of chemo-phototherapy has gained increasing prominence due to its remarkable synergistic antitumor effects. Methods: Hydrophilic sericin (Ser) was linked to antitumor drug doxorubicin (DOX) via a disulfide bond. The obtained Ser-ss-DOX conjugate was characterized by Fourier-transform infrared spectroscopy (FTIR), proton nuclear magnetic resonance ( Results: The Ser-ss-DOX conjugate was successfully synthesized. Ser-ss-DOX and Ser-ss-DOX/IR780 nanoparticles were spherical in shape, and their particle sizes measured by DLS were 326 and 190 nm, respectively. IR780 was in an amorphous state within the Ser-ss-DOX/IR780 nanoparticles. The loading contents of DOX and IR780 were 8.26% and 2.78%, respectively. Ser-ss-DOX/IR780 exhibited ideal photothermal properties in vitro and reduction-sensitive drug release in a high glutathione (GSH) environment. Ser-ss-DOX/IR780 displayed higher cellular uptake in 4T1 cells than Ser-ss-DOX and free DOX. Under 808 nm laser irradiation, Ser-ss-DOX/IR780 showed a strong capacity to generate ROS. Importantly, Ser-ss-DOX/IR780 with laser irradiation effectively inhibited the growth of 4T1 cells and 3D multicellular tumor spheroids. Conclusion: This work demonstrated that Ser-ss-DOX/IR780 integrated dual functionalities of chemotherapy and phototherapy, thereby enabling substantial potential for application in tumor treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.